“The growth is due to the launch of new cardiovascular, oncology and over-the-counter products,” said company general manager Dragos Damian.
He said the company is on track for this year’s target of a 10% growth in turnover. In 2012, the company had a turnover of RON450 million (EUR100 million), up 7% on the year.
In the first quarter of the year, Terapia Ranbaxy’s turnover increased around 10% and at the end of the first half the growth was of 8%.
Damian said it was hard to make estimates for 2014, citing a hostile environment for generics producers.
The company will focus on completing investments on its platform in Cluj-Napoca, a EUR10 million project that includes European funds and that will create 30 new jobs in the next 15 months.
At the end of last year, the company had 850 employees. The production line in Cluj-Napoca makes 200 types of oral and injectable drugs.
According to company data and market surveys by Cegedim Romania, Ranbaxy ranks ninth on the local pharmaceutical market, with a 3.8% market share.
Sales of medicines in Romania, at distribution prices, fell 3.3% on the year in the third quarter, to RON2.79 billion, according to Cegedim.
Ranbaxy Laboratories, the largest drug maker in India, bought 96.7% of Terapia Cluj-Napoca in March 2006 from investment fund Advent International for $324 million. In 2008, Japanese pharmaceutical group Daiichi Sankyo became the majority shareholder of Ranbaxy Laboratories.